Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 04:24:55 2024-06-20 EDT			5-day change	1st Jan Change
93.71 ^CHF	-0.22%		-0.75%	+10.23%

10:20am	MorphoSys Set to Delist Following Acquisition by Novartis	MT
10:18am	MorphoSys Inks Delisting Agreement After Takeover by Novartis	MT

NOVARTIS AG : Berenberg remains Neutral

May 23, 2024 at 02:07 am

Berenberg analyst Kerry Holford maintains his Neutral opinion on the stock. The target price is reviewed upwards from CHF 74 to CHF 77.

Latest news about Novartis AG

MorphoSys Set to Delist Following Acquisition by Novartis	04:20am	MT
MorphoSys Inks Delisting Agreement After Takeover by Novartis	04:18am	MT
Biotech company Morphosys will soon disappear from the stock exchange	03:57am	RE
EU regulator mandates label updates on CAR-T cancer therapies	06-14	RE
PeptiDream and Novartis Agreement Becomes Effective with 28.3 Billion Yen Upfront Payment	06-14	MT
Nkarta, Inc. Appoints George Vratsanos as Board of Directors	06-13	CI
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment	06-13	CI
NOVARTIS AG : JP Morgan reiterates its Neutral rating	06-11	ZD
Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy	06-07	MT
Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug	06-07	MT
AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation	06-06	MT
Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists	06-06	RE
Novartis, Roche, Biogen, Samsung Bioepis in Italy Eye-Medicine Probe	06-06	DJ
Novartis and others face Italy antitrust probe over eye drug	06-06	RE
Three newcomers to the MDax - Rational, TUI and Traton move up	06-06	RE
Cytokinetics CEO Says Board Would Have Backed Actionable Buyout	06-05	DJ
The odds of rates getting cut in 2024 may be better than you think	06-05
NOVARTIS AG : Deutsche Bank maintains a Buy rating	06-05	ZD
Bank Vontobel Lifts Price Target on Novartis, Maintains Buy Recommendation	06-04	MT
NOVARTIS AG : JP Morgan remains Neutral	06-03	ZD
NOVARTIS AG : Buy rating from Goldman Sachs	06-03	ZD
NOVARTIS : UBS reiterates buy recommendation after ASCO	06-03	CF
SMA Solar and Morphosys are about to leave the MDax	06-03	RE
NOVARTIS AG : UBS gives a Buy rating	06-03	ZD
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	06-02	RE

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

2024-06-19 - JP Morgan European Healthcare Conference

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : 2024 has started on a strong note; guidance upgraded

April 23, 2024 at 01:24 pm

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 07:18 am

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

106.2 USD

Average target price

110.3 USD

Spread / Average Target

+3.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+10.23%	217B
ELI LILLY AND COMPANY	+52.93%	803B
NOVO NORDISK A/S	+40.67%	631B
JOHNSON & JOHNSON	-7.08%	351B
MERCK & CO., INC.	+17.40%	324B
ABBVIE INC.	+10.58%	303B
ASTRAZENECA PLC	+16.47%	243B
ROCHE HOLDING AG	+2.13%	228B
AMGEN INC.	+6.24%	164B
PFIZER, INC.	-4.79%	155B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

NOVARTIS AG : Berenberg remains Neutral

Latest news about Novartis AG

Chart Novartis AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novartis AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals